Drawing for MANNKIND

USPTO serial 88753466

MANNKIND

Reviewed by CopyMark Law Group

Reg. 6278902Status 700Renewal
Filing date
Status date
Registration date
Feb 23, 2021
Examiner
GARTNER, JOHN M
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MANNKIND?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jaclyne D. Wallace

Jaclyne D. Wallace Foley & Lardner LLP321 North Clark Street, Suite 3000Chicago, IL 60654UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
041Arranging and conducting conferences, seminars and non-downloadable webinars in the field of health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing podcasts in the field of health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticalsACTIVEFeb 6, 2020
044Medical information services, including providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and/or drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocolsACTIVEFeb 6, 2020

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 23, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 3, 2025ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Jun 14, 2024NOSUNOTICE OF SUIT—
Jun 14, 2024NOSUNOTICE OF SUIT—
Jun 14, 2024NOSUNOTICE OF SUIT—
Jun 14, 2024NOSUNOTICE OF SUIT—
Feb 23, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 21, 2021SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jan 20, 2021CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jan 7, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 6, 2021SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jan 6, 2021EX1GSOU EXTENSION 1 GRANTED—
Jan 4, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 14, 2020IUAFUSE AMENDMENT FILED—
Dec 14, 2020EXT1SOU EXTENSION 1 FILED—
Dec 14, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 14, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Nov 19, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 19, 2020EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Nov 19, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 19, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 30, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 5, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 5, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 15, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 26, 2020ALIEASSIGNED TO LIE—
Mar 20, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 20, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Mar 20, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 20, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 20, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 19, 2020DOCKASSIGNED TO EXAMINER—
Jan 14, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 13, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance